A world-first trial of a personalised vaccine for children with deadly brain cancers will be rolled out in eight hospitals throughout Australia later this year.  Read more: https://www.abc.net.au/news/2026-02-03/brain-cancer-vaccine-trial-for-children/106294532

A new national study highlights both common ground and key diverging factors between parents and clinicians on what psychosocial needs matter most for children with cancer. Read more: https://journals.lww.com/oncology-times/fulltext/2026/02000/parents___clinicians_diverge_on_psychosocial.2.aspx

Knowledge Mobilization Group seeks to understand the knowledge mobilization needs of the childhood cancer community from the perspectives of both children and adults. Read more: https://www.mcgill.ca/nursing/article/pan-canadian-research-team-dedicated-improving-lives-children-cancer-and-their-families

The FDA approved a larger nelarabine vial to improve dosing flexibility and simplify treatment for adult and pediatric patients with T-ALL and T-LBL.   Read more: https://www.curetoday.com/view/fda-approves-larger-nelarabine-vial-for-some-leukemias-and-lymphomas

A new research collaboration aims to transform the treatment of children with brain tumors by identifying hidden genetic drivers that current diagnostic technologies often miss. Read more: https://jagwire.augusta.edu/revolutionary-genome-mapping-tech-targets-childhood-brain-cancers/

Children with Down syndrome have a significantly increased risk of leukemia, while adults have a lower risk of several common solid tumors, according to a new register study from Karolinska Institutet published in the British Journal of Cancer. The results may contribute to more tailored cancer screening guidelines. Read more: https://news.ki.se/a-unique-cancer-risk-profile-in-down-syndrome-higher-leukemia-risk-in-childhood

Pediatric cancers follow their own biological rules, and understanding this distinction is the foundation of effective research. For Charles W.M. Roberts, MD, PhD, executive vice president and St. Jude Comprehensive Cancer Center director, this difference underpins his approach to discovering the next generation of therapies for children. Read more: https://www.stjude.org/research/progress/2026/why-biology-demands-different-playbook-for-kids-with-cancer.html

"The relapse usually happens in the first two years after diagnosis, Winters says, and is much harder to treat than the original occurrence. The current method of predicting relapse involves a bone marrow sample that is tested for specific proteins that indicate the presence of cancer, but Winters is interested in a genetic test that is more accurate and can be conducted via a simple blood draw." Read more: https://news.cuanschutz.edu/cancer-center/predict-relapse-pediatric-a

Researchers at Oncode Institute and Princess Máxima Center have developed a new human model of the brainstem that is changing how one of the most aggressive childhood brain cancers can be studied. Read more: https://www.zonmw.nl/en/news/new-human-brain-model-deadly-childhood-brain-cancer

"The guidelines are clear: Survivorship care is important. But in many cases, care does not occur, and our study combines evidence from many sources to explain why" Read more: https://medicalxpress.com/news/2026-01-major-highlights-barriers-childhood-cancer.html